CuraSen Therapeutics Announces $54.5 Million Series A Financing
SAN MATEO, Calif., Oct. 17, 2018 — CuraSen Therapeutics, Inc., a privately held biotechnology company focused on developing therapies to treat neurodegenerative diseases, today announced the closing of a $54.5 million Series A financing. Led by New Leaf Venture Partners, the investor syndicate includes Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Pappas Capital. CuraSen is developing small molecule drugs targeting a novel mechanism in the brain to alleviate disabling symptoms and modify disease pathology in patients who suffer from less common (orphan) neurodegenerative disorders as well as Parkinson’s Disease and Alzheimer’s Disease.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.